Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to […]
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to
Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University Read More »
Today, Biogen announced the publication of results from the pivotal Phase 2/3 DEVOTE study in Nature Medicine, highlighting the potential benefits of a high-dose regimen of nusinersen for people living with spinal muscular atrophy (SMA). The study evaluated a higher loading and maintenance dose regimen of nusinersen and demonstrated improvements across key areas, including motor
Biogen Announces Results from the Phase 2/3 DEVOTE Study Read More »
On February 3rd, Congress approved and the President signed into law key research and legislative priorities that Cure SMA and individuals with spinal muscular atrophy (SMA) and their families have been advocating for over the past year. The Consolidated Appropriations Act of 2026 includes the following provisions that will benefit children and adults with SMA
SMA Community Research and Legislative Priorities Finalized in New Federal Law Read More »
Genentech recently released an update on their continued collaboration with the SMA community and Evrysdi® tablet updates. They will continue to provide timely updates as they become available. Read the full community update letter here. “Looking back, 2025 was a time that was undeniably defined as a year of great change. We successfully navigated shifts,
Genentech Releases Winter SMA Community Update Letter Read More »
Cure SMA warmly invites you to join us at one of our 2026 Walk-n-Roll events—where community meets impact! This year, you can register and start fundraising for both spring and fall events right now. Walk-n-Roll isn’t just a fundraiser; it’s a celebration of progress, hope, and togetherness. It’s a chance to gather with others who
All 2026 Walk-n-Roll Events Are Open Read More »
Watch the video and see how far we’ve come and the future we’re building together. Donate to Support the SMA Community Your support accelerates research, strengthens advocacy, and expands critical family services for individuals and families living with SMA. Make your impact today.
Together, We’re Changing the Story of SMA Read More »
Earlier this year, Cure SMA launched an expanded Phase 10 of the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, SMA Europe, Cure SMA, and other nonprofit organizations to share information, ideas, and data to benefit the broader SMA community. Through the Industry Collaboration, we fund projects to ensure
Cure SMA Shares Updates on the Phase 10 SMA Industry Collaboration Read More »
Today is Giving Tuesday, and there’s an incredible opportunity to double your impact! The Luke 18:1 Foundation has stepped forward with a $50,000 gift and invited our community to double the impact in the next 24 hours. By giving today, you help us rise to this special Giving Tuesday challenge and bring meaningful support to children,
Double Your Impact this Giving Tuesday! Read More »
Novartis today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Itvisma (onasemnogene abeparvovec-brve) to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). Itvisma (onasemnogene abeparvovec-brve) is a gene therapy that works by delivering a functional copy of the SMN1 gene directly to motor neurons, helping the body restore
Novartis Receives FDA Approval of Itvisma for the Treatment of SMA Read More »
